Literature DB >> 1977703

The medical management of reflux esophagitis. Role of antacids and acid inhibition.

S J Sontag1.   

Abstract

Of the more than 60 million adult Americans who have heartburn at least once a month, 60% choose over-the-counter medication rather than consulting their physician. Those individuals who do seek medical advice for reflux symptoms will probably receive a prescription for an H2-receptor antagonist, although in many instances simple life-style changes and occasional use of antacids may provide effective therapy. Patients who have severe esophagitis or reflux symptoms unresponsive to H2-receptor antagonists may be treated with a more potent antisecretory agent (proton pump inhibitor). The author discusses the role of antacids and acid inhibition in the treatment of gastroesophageal reflux disease. The results of the clinical trials with the H2-receptor antagonists, cimetidine, ranitidine, famotidine, and nizatidine, and the proton pump inhibitor omeprazole, are compared and contrasted.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1977703

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  19 in total

Review 1.  Endoluminal and transluminal surgery: current status and future possibilities.

Authors:  A Malik; J D Mellinger; J W Hazey; B J Dunkin; B V MacFadyen
Journal:  Surg Endosc       Date:  2006-07-24       Impact factor: 4.584

2.  Laryngopharyngeal Reflux and Functional Laryngeal Disorder: Perspective and Common Practice of the General Gastroenterologist.

Authors:  Dhyanesh A Patel; Michael Blanco; Michael F Vaezi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-09

3.  Development and Validation of a Mucosal Impedance Contour Analysis System to Distinguish Esophageal Disorders.

Authors:  Dhyanesh A Patel; Tina Higginbotham; James C Slaughter; Muhammad Aslam; Elif Yuksel; David Katzka; C Prakash Gyawali; Melina Mashi; John Pandolfino; Michael F Vaezi
Journal:  Gastroenterology       Date:  2019-01-31       Impact factor: 22.682

Review 4.  Oesophageal mucosal diseases in the elderly.

Authors:  R Ouatu-Lascar; G Triadafilopoulos
Journal:  Drugs Aging       Date:  1998-04       Impact factor: 3.923

5.  The impact of previous fundoplication on laparoscopic gastric bypass outcomes: a case-control evaluation.

Authors:  Anna Ibele; Michael Garren; Jon Gould
Journal:  Surg Endosc       Date:  2011-08-20       Impact factor: 4.584

Review 6.  On-demand and intermittent therapy for gastro-oesophageal reflux disease: economic considerations.

Authors:  John M Inadomi
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

7.  Multicenter prospective evaluation of laparoscopic antireflux surgery. Preliminary report.

Authors:  A Cuschieri; J Hunter; B Wolfe; L L Swanstrom; W Hutson
Journal:  Surg Endosc       Date:  1993 Nov-Dec       Impact factor: 4.584

8.  Treatment of erosive reflux esophagitis resistant to H2-receptor antagonist therapy. Lansoprazole, a new proton pump inhibitor.

Authors:  M Robinson; D R Campbell; S Sontag; S M Sabesin
Journal:  Dig Dis Sci       Date:  1995-03       Impact factor: 3.199

9.  Does omeprazole (Prilosec) improve respiratory function in asthmatics with gastroesophageal reflux? A double-blind, placebo-controlled crossover study.

Authors:  J H Meier; P R McNally; M Punja; S R Freeman; R H Sudduth; N Stocker; M Perry; H S Spaulding
Journal:  Dig Dis Sci       Date:  1994-10       Impact factor: 3.199

10.  GERD-related health care utilization, therapy, and reasons for transfer of GERD patients between primary care providers and gastroenterologists in a US managed care setting.

Authors:  Rachel Halpern; Smita Kothari; Mahesh Fuldeore; Victoria Zarotsky; Victoria Porter; Omar Dabbous; Jay L Goldstein
Journal:  Dig Dis Sci       Date:  2009-08-21       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.